Dovitinib Dilactic acidCAS# 852433-84-2 |
- Vatalanib (PTK787) 2HCl
Catalog No.:BCC1111
CAS No.:212141-51-0
- Ki8751
Catalog No.:BCC1116
CAS No.:228559-41-9
- Cediranib (AZD217)
Catalog No.:BCC1121
CAS No.:288383-20-0
- Lenvatinib (E7080)
Catalog No.:BCC1172
CAS No.:417716-92-8
- Tivozanib (AV-951)
Catalog No.:BCC1179
CAS No.:475108-18-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 852433-84-2 | SDF | Download SDF |
| PubChem ID | 135985126 | Appearance | Powder |
| Formula | C27H33FN6O7 | M.Wt | 572.59 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one;2-hydroxypropanoic acid | ||
| SMILES | CC(C(=O)O)O.CC(C(=O)O)O.CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N | ||
| Standard InChIKey | XXLPVQZYQCGXOV-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C21H21FN6O.2C3H6O3/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;2*1-2(4)3(5)6/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2*2,4H,1H3,(H,5,6) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Dovitinib Dilactic acid Dilution Calculator
Dovitinib Dilactic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.7465 mL | 8.7323 mL | 17.4645 mL | 34.929 mL | 43.6613 mL |
| 5 mM | 0.3493 mL | 1.7465 mL | 3.4929 mL | 6.9858 mL | 8.7323 mL |
| 10 mM | 0.1746 mL | 0.8732 mL | 1.7465 mL | 3.4929 mL | 4.3661 mL |
| 50 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.6986 mL | 0.8732 mL |
| 100 mM | 0.0175 mL | 0.0873 mL | 0.1746 mL | 0.3493 mL | 0.4366 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Dovitinib Dilactic acid is a potent, non-specific growth factor receptor kinase inhibitor with effects against FLT-3, c-KIT, VEGFR, PDGFRß and CSF-1R, respectively.
- Necrostatin 2 S enantiomer
Catalog No.:BCC2078
CAS No.:852391-20-9
- Necrostatin 2
Catalog No.:BCC1793
CAS No.:852391-19-6
- Necrostatin 2 racemate
Catalog No.:BCC2077
CAS No.:852391-15-2
- 6-Methyl-7-O-methylaromadendrin
Catalog No.:BCN4010
CAS No.:852385-13-8
- BAPTA
Catalog No.:BCC7483
CAS No.:85233-19-8
- TOK-001
Catalog No.:BCC3910
CAS No.:851983-85-2
- RuBi-4AP
Catalog No.:BCC6044
CAS No.:851956-02-0
- ADX-47273
Catalog No.:BCC4598
CAS No.:851881-60-2
- 3-(3-Chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one
Catalog No.:BCC8587
CAS No.:85175-59-3
- PF 514273
Catalog No.:BCC7746
CAS No.:851728-60-4
- OC000459
Catalog No.:BCC4507
CAS No.:851723-84-7, 950688-14-9 (sodium salt)
- Curculigoside C
Catalog No.:BCN3696
CAS No.:851713-74-1
- Futokadsurin C
Catalog No.:BCN6402
CAS No.:852459-91-7
- MC1568
Catalog No.:BCC2151
CAS No.:852475-26-4
- Heteronoside
Catalog No.:BCN4401
CAS No.:852638-61-0
- (±)-LY 395756
Catalog No.:BCC7623
CAS No.:852679-66-4
- ABT-737
Catalog No.:BCC3613
CAS No.:852808-04-9
- TP-808
Catalog No.:BCC6450
CAS No.:852821-06-8
- Sculponeatin A
Catalog No.:BCN4402
CAS No.:85287-60-1
- 2,3-Dihydropodocarpusflavone A
Catalog No.:BCN6668
CAS No.:852875-96-8
- TCN 201
Catalog No.:BCC6122
CAS No.:852918-02-6
- 20(21)-Dehydrolucidenic acid A
Catalog No.:BCN2940
CAS No.:852936-69-7
- Dehydroepiandrosterone acetate
Catalog No.:BCC8929
CAS No.:853-23-6
- Anthraquinone-1,5-disulfonic acid disodium salt
Catalog No.:BCC8833
CAS No.:853-35-0
Dovitinib dilactic acid reduces tumor growth and tumor-induced bone changes in an experimental breast cancer bone growth model.[Pubmed:30956945]
J Bone Oncol. 2019 Mar 19;16:100232.
Advanced breast cancer has a high incidence of bone metastases. In bone, breast cancer cells induce osteolytic or mixed bone lesions by inducing an imbalance in bone formation and resorption. Activated fibroblast growth factor receptors (FGFRs) are important in regulation of tumor growth and bone remodeling. In this study we used FGFR1 and FGFR2 gene amplifications containing human MFM223 breast cancer cells in an experimental xenograft model of breast cancer bone growth using intratibial inoculation technique. This model mimics bone metastases in breast cancer patients. The effects of an FGFR inhibitor, Dovitinib Dilactic acid (TKI258) on tumor growth and tumor-induced bone changes were evaluated. Cancer-induced bone lesions were smaller in dovitinib-treated mice as evaluated by X-ray imaging. Peripheral quantitative computed tomography imaging showed higher total and cortical bone mineral content and cortical bone mineral density in dovitinib-treated mice, suggesting better preserved bone mass. CatWalk gait analysis indicated that dovitinib-treated mice experienced less cancer-induced bone pain in the tumor-bearing leg. A trend towards decreased tumor growth and metabolic activity was observed in dovitinib-treated mice quantified by positron emission tomography imaging with 2-[(18)F]fluoro-2-deoxy-D-glucose at the endpoint. We conclude that dovitinib treatment decreased tumor burden, cancer-induced changes in bone, and bone pain. The results suggest that targeting FGFRs could be beneficial in breast cancer patients with bone metastases.
